Evidence map›Paper›PMID 25789320›Full record

ReviewBioMed research international2015

Alpha-linolenic acid: an omega-3 fatty acid with neuroprotective properties-ready for use in the stroke clinic?

Nicolas Blondeau, Robert H Lipsky, Miled Bourourou, Mark W Duncan, Philip B Gorelick, Ann M Marini

Open access · hybridAbstract readReview
In one paragraph

Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 1 synthesis or guideline pooled it, 201 citations in OpenAlex.

  1. Omega-3 fatty acids for intermittent claudication.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Nutrients and Bioactive Compounds fromInternational journal of molecular sciences · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 3 countries.

Nicolas BlondeauInstitut de Pharmacologie Moléculaire et Cellulaire, Université de Nice Sophia Antipolis, 660 route des Lucioles, Valbonne, 06560 Sophia Antipolis, France ; CNRS, IPMC, 06560 Sophia Antipolis, France.
Robert H LipskyInova Neuroscience Institute, Inova Health System, Falls Church, VA 22042, USA.
Miled BourourouInstitut de Pharmacologie Moléculaire et Cellulaire, Université de Nice Sophia Antipolis, 660 route des Lucioles, Valbonne, 06560 Sophia Antipolis, France ; CNRS, IPMC, 06560 Sophia Antipolis, France.
Mark W DuncanDivision of Endocrinology, Diabetes & Metabolism, Department of Medicine, School of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO 80045, USA ; Obesity Research Center, College of Medicine, King Saud University, Riyadh 11461, Saudi Arabia.
Philip B GorelickMercy Health Hauenstein Neurosciences & Department of Translational Science and Molecular Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA.
Ann M MariniDepartment of Neurology and Program in Neuroscience, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA.
Centre National de la Recherche Scientifique · FRInova Health System · USInstitut de Pharmacologie Moléculaire et Cellulaire · FRKing Saud University · SAMercy Health Saint Mary's · USUniformed Services University of the Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha-linolenic acid (ALA) is plant-based essential omega-3 polyunsaturated fatty acids that must be obtained through the diet. This could explain in part why the severe deficiency in omega-3 intake pointed by numerous epidemiologic studies may increase the brain's vulnerability representing an important risk factor in the development and/or deterioration of certain cardio- and neuropathologies. The roles of ALA in neurological disorders remain unclear, especially in stroke that is a leading cause of death. We and others have identified ALA as a potential nutraceutical to protect the brain from stroke, characterized by its pleiotropic effects in neuroprotection, vasodilation of brain arteries, and neuroplasticity. This review highlights how chronic administration of ALA protects against rodent models of hypoxic-ischemic injury and exerts an anti-depressant-like activity, effects that likely involve multiple mechanisms in brain, and may be applied in stroke prevention. One major effect may be through an increase in mature brain-derived neurotrophic factor (BDNF), a widely expressed protein in brain that plays critical roles in neuronal maintenance, and learning and memory. Understanding the precise roles of ALA in neurological disorders will provide the underpinnings for the development of new therapies for patients and families who could be devastated by these disorders.

Indexed as

alpha-Linolenic AcidAnimalsBrainBrain-Derived Neurotrophic FactorFatty Acids, Omega-3HumansNeuroprotective AgentsStrokealpha-Linolenic AcidBrain-Derived Neurotrophic FactorFatty Acids, Omega-3Neuroprotective Agents

Identifiers

PMID25789320
PMCPMC4350958
OpenAlexW2048280281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.